Baseline Characteristics of the TOPaZ Study: Randomised Trial of Teriparatide and Zoledronic Acid Compared with Standard Care in Adults with Osteogenesis Imperfecta
Calcified Tissue International · 2025
DOI: 10.1007/s00223-025-01440-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Calcified Tissue International, 2025. Verfasst von Jannie Dahl Hald und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Osteogenesis Imperfecta, Zoledronic Acid, Bone Density Conservation Agents, Teriparatide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Efficacy and Mechanism Evaluation Programme.
Abstract (Originalsprache)
Introduction
Osteogenesis imperfecta (OI) is a rare disorder causing multiple fractures throughout life. No treatment has been shown to reduce the risk of fractures in OI. Here, we present the baseline characteristics of participants in the T reatment of O steogenesis Imperfecta with P arathyroid Hormone a nd Z oledronic Acid (TOPaZ) trial. The aim of the trial is to determine whether teriparatide and zoledronic acid are superior to standard care in reducing the risk of clinical fractures.
Methods
We summarised data on the baseline characteristics of TOPaZ participants, including demographics, genetic diagnosis, clinical features, bone density measurements, previous treatments, and fracture history.
Results
We recruited 350 adults with a clinical diagnosis of OI in 27 European referral centres between June 2017 and October 2022. Overall, 266 (76.2%) had type I OI, 55 (15.8%) had type IV, and 19 (5.4%) had type III. The type was unknown in 9 (2.6%). Blue sclera were noted in 80.8%, and 35.8% had dentinogenesis imperfecta. Bisphosphonates had been administered to 28.1% in the 2 years prior to enrolment. Pathogenic variants in COL1A1 or COL1A2 were found in 87.6%. Fractures occurring in the 2 years prior to enrolment were not associated with bone density.
Conclusions
The TOPaZ population represents a unique cohort with which to study the genetic epidemiology and outcome of OI in relation to bone density and biochemical markers of bone turnover. When the trial reports, it will also provide new insights into the effect of an anabolic therapy, followed by antiresorptive treatment in the management of OI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Centre for Rare Disorders, Aarhus University Hospital, Aarhus, Denmark.
- Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
- Metabolic Bone Clinic, Royal National Orthopaedic Hospital NHS Trust, London, UK.
- Metabolic Bone Centre, University of Sheffield, Sheffield, UK.
- Cambridge University Hospitals NHS Trust, Addenbrookes Hospital, Cambridge, UK.
ORCID-Profile: Stuart H Ralston
Förderung
- Efficacy and Mechanism Evaluation Programme
Zitieren
APA
Hald, J. D., Weir, C., Keerie, C., Dewar, L., MacLean, M., Milne, L., Keen, R., Walsh, J., Poole, K., Langdahl, B., Lindsay, J. R., Ghouri, N., Hollick, R. J., Aspray, T., Crowley, R. K., Cohen-Solal, M., Hassan-Smith, Z., Tuck, S., Curtis, E., …, & Ralston, S. H. (2025). Baseline Characteristics of the TOPaZ Study: Randomised Trial of Teriparatide and Zoledronic Acid Compared with Standard Care in Adults with Osteogenesis Imperfecta. Calcified Tissue International. https://doi.org/10.1007/s00223-025-01440-3
Vancouver
Hald JD, Weir C, Keerie C, Dewar L, MacLean M, Milne L, et al. Baseline Characteristics of the TOPaZ Study: Randomised Trial of Teriparatide and Zoledronic Acid Compared with Standard Care in Adults with Osteogenesis Imperfecta. Calcified Tissue International. 2025. doi:10.1007/s00223-025-01440-3
BibTeX
@article{Hald2025,
author = {Hald, Jannie Dahl and Weir, Christopher and Keerie, Catriona and Dewar, Lorna and MacLean, Morag and Milne, Lynsey and Keen, Richard and Walsh, Jennifer and Poole, Kenneth and Langdahl, Bente and Lindsay, John R and Ghouri, Nazim and Hollick, Rosemary J and Aspray, Terry and Crowley, Rachel K and Cohen-Solal, Martine and Hassan-Smith, Zaki and Tuck, Stephen and Curtis, Elizabeth and Harvey, Nick and Eekhoff, E Marelise W and Feenstra, Johannes and Hampson, Geeta and Stone, Mike and Turton, Jane and Patel, Prashanth and Siddiqi, Mashood and Munro, Robin and Roy, Matthew and Paskins, Zoe and Narayanan, Deepa and Malcolm, Ellen and Javaid, Muhammad Kassim and Osborne, Patricia and Tang, Jonathan C Y and Lam, Wayne and Moore, David and Black, Holly A and Duckworth, Andrew D and Makaram, Navnit and Guo, Tianyu and Stenhouse, Gregor and Ralston, Stuart H},
title = {Baseline Characteristics of the TOPaZ Study: Randomised Trial of Teriparatide and Zoledronic Acid Compared with Standard Care in Adults with Osteogenesis Imperfecta},
journal = {Calcified Tissue International},
year = {2025},
doi = {10.1007/s00223-025-01440-3}
}
EUVIMED